ACRS Overview
Upcoming Projects (ACRS)
Executed Projects (ACRS)
-
A Second Opinion: Discussing the potential of Kiniksa's KPL-404 and Aclaris's zunsemetinib (ATI-450) for treatment of patients with rheumatoid arthritis
Tickers: KNSA, ACRS
Executed On: Aug 17, 2023 at 05:00 PM EDT -
Discussing the potential of Kiniksa's KPL-404 and Aclaris's zunsemetinib (ATI-450) for treatment of patients with rheumatoid arthritis
Tickers: KNSA, ACRS
Executed On: Aug 03, 2023 at 05:30 PM EDT
Upcoming & Overdue Catalysts (ACRS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ACRS)
-
Rheumatoid Arthritis, Phase 2a data due 1H 2021.
Ticker: ACRS
Occurred on: Jan 19, 2021 -
NDA filing for A-101 in Seborrheic keratosis (SK) expected in 1Q 2017
Ticker: ACRS
Occurred on: Feb 27, 2017 -
Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition
Ticker: ACRS
Occurred on: Nov 15, 2016 -
Aclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
Ticker: ACRS
Occurred on: Aug 18, 2016
Strategic Initiatives (ACRS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
